Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

6 de janeiro de 2021 atualizado por: Innocoll

A Phase II, Randomized, Single Dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx® Bupivacaine Implant in Men After Open Mesh Herniorrhaphy

The purpose of this study is to determine whether the CollaRx Bupivacaine implant is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 24 hours after herniorrhaphy.

Visão geral do estudo

Descrição detalhada

Inguinal herniorrhaphy is a common surgery; and common surgical methods used include laparoscopic and open placement of synthetic mesh. The use of synthetic mesh can greatly reduce the risk of hernia recurrence regardless of the method used for its placement. Managing postoperative pain and preventing morbidity after open mesh herniorrhaphy remain considerable medical challenges.

Bupivacaine is a local anesthetic (pain medicine) that has an established safety profile. Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin flat sponge made out of collagen that comes from cow tendons and contains bupivacaine. When inserted into a surgical site, the collagen breaks down and bupivacaine is released at the site but very little is absorbed into the blood stream. The high levels of bupivacaine at the surgical site may result in less pain for several days after surgery.

This study will compare the amount of narcotic pain medication required after surgery in patients who receive either the CollaRx Bupivacaine implant or a plain collagen sponge.

Tipo de estudo

Intervencional

Inscrição (Real)

53

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • Anaheim, California, Estados Unidos, 92801
        • Advanced Clinical Research Institute

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  • Has body mass index (BMI) > 19 and < 40 kg/m2.
  • Has a planned unilateral inguinal herniorrhaphy (open mesh, tension free technique) to be performed according to standard surgical technique under general anesthesia.
  • Has a risk classification of I, II or III according to the ASA.
  • Is free of other physical or mental conditions that, in the opinion of the Investigator, may confound the quantification of postoperative pain after herniorrhaphy.
  • Has the ability and willingness to comply with the study procedures and the use of the pain scales.
  • Is willing to use only permitted medications and anesthetics throughout the study.
  • Is willing to use opioid rescue analgesia for moderate to severe incisional pain only.
  • Must voluntarily sign and date an informed consent form (ICF) that is approved by an Institutional Review Board (IRB) before the conduct of any study specific procedures.
  • Must be able to fluently speak and understand English and be able to provide meaningful written informed consent for the study.

Exclusion Criteria:

  • Has a known hypersensitivity to amide local anesthetics, opioids, bovine products or inactive ingredients of the test article.
  • Is scheduled for bilateral inguinal herniorrhaphy.
  • Has undergone a prior herniorrhaphy on the side that is currently scheduled for repair.
  • Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.
  • Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and grapefruit juice).
  • Has used long acting analgesics within 24 hours of surgery. Short acting analgesics such as acetaminophen may be used on the day of surgery
  • Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on a stable dose regimen for ≥ 30 days before Screening.
  • Has undergone major surgery within 3 months of the scheduled herniorrhaphy.
  • Has known or suspected history of alcohol or drug abuse or misuse within 3 years of Screening or evidence of tolerance or physical dependency on opioid analgesics or sedative-hypnotic medications.
  • Has used opioids or tramadol on an extended daily basis (> 7 days) before surgery. Patients who, in the Investigator's opinion, are developing opioid tolerance are to be excluded.
  • Has impaired liver function, aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/bilirubin ≥ 3.0 times the upper limit of normal (ULN), active hepatic disease, evidence of clinically significant liver disease or another condition (eg, alcoholism, cirrhosis or hepatitis) that may suggest the potential for an increased susceptibility to hepatic toxicity with exposure to test article.
  • Has any clinically significant unstable cardiac, neurological, immunological, renal or hematological disease or any other condition that, in the opinion of the Investigator, could compromise the patient's welfare, ability to communicate with the study staff or otherwise contraindicate study participation.
  • Is judged by the Investigator to be at risk for infection or slow wound healing.
  • Has a chronic painful condition that might confound the assessment of pain associated with the herniorrhaphy.
  • Routinely uses pain medication that, in the opinion of the Investigator, could confound the pain assessments during the study.
  • Has been treated with agents that could affect the analgesic response (such as central alpha agents, neuroleptic agents and other antipsychotic agents) within 2 weeks of surgery.
  • Has been treated with monoamine oxidase inhibitors (MAOIs) within 10 days of surgery.
  • Has been treated with systemic corticosteroids within 7 days of surgery (inhaled and topical corticosteroids are allowed).
  • Has participated in a clinical trial within 30 days of surgery.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: 1
Two, 5x5cm bupivacaine collagen sponges implanted during surgery
collagen; Bupivacaine hydrocholoride
Outros nomes:
  • CollaRx Bupivacaine Implant
Comparador de Placebo: 2
Placebo collagen sponge implanted during surgery
collagen
Outros nomes:
  • Placebo

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours
Prazo: 0 to 24 hours postoperatively
Total Use of Opioid Rescue Analgesia (mg) Over 0 to 24 Hour - number count - higher score means worse outcome
0 to 24 hours postoperatively

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Total Use of Opioid Rescue Analgesia Over 0 to 48 Hours
Prazo: 0 to 48 hours postoperatively
Number count. Higher score means worse outcome
0 to 48 hours postoperatively
Total Use of Opioid Rescue Analgesia Over 0 to 72 Hours
Prazo: 0 to 72 hours postoperatively
Number count - higher score means worse outcome
0 to 72 hours postoperatively
Summed Pain Intensity VAS Scores (VAS at Rest and After Cough)
Prazo: 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
Summed pain intensity (SPI) (VAS at rest and after cough): - For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor. Each timepoint consist of two measurements (Resting & Coughing) - The lower the score the better outcome for the patient. The highest total score (worst possible score) for the 10 timepoints would be 2000.
1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0
Patient's Global Evaluation of the Study Treatment on a 5 Point Likert Scale
Prazo: At 72 hours after time 0
For the 5-point categorical scale global evaluation of study treatment, the patient was instructed to score his global evaluation of the pain control provided by the study treatment where: 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent
At 72 hours after time 0
VAS Pain Intensity Scores Over Time
Prazo: At 1, 1.5, 2,3,4,5,6,24,48,72 Hours
For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.
At 1, 1.5, 2,3,4,5,6,24,48,72 Hours
Categorical Pain Intensity Scores Over Time - AT REST
Prazo: At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = "none," 1 = "mild," 2 = "moderate" and 3 = "severe."
At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
Categorical Pain Relief Scores Over Time - AT REST
Prazo: At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.
At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
Categorical Pain Intensity Scores Over Time (After Cough)
Prazo: At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = "none," 1 = "mild," 2 = "moderate" and 3 = "severe." Higher Score means a worse outcome
At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
Categorical Pain Relief Scores Over Time (After Cough)
Prazo: At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours
For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.
At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de março de 2008

Conclusão Primária (Real)

29 de janeiro de 2009

Conclusão do estudo (Real)

29 de janeiro de 2009

Datas de inscrição no estudo

Enviado pela primeira vez

20 de fevereiro de 2008

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de fevereiro de 2008

Primeira postagem (Estimativa)

29 de fevereiro de 2008

Atualizações de registro de estudo

Última Atualização Postada (Real)

11 de janeiro de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de janeiro de 2021

Última verificação

1 de janeiro de 2021

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever